Similar articles

• Cost utility of drugs for multiple sclerosis. Analysis goes too far.

  Ellis SJ. Ellis SJ. BMJ. 2000 May 27;320(7247):1475-6. BMJ. 2000. PMID: 10877571 No abstract available.
• [A short history of beta-interferon therapy of multiple sclerosis].

  Stock G, Horowski R. Stock G, et al. Med Klin (Munich). 2001 Sep 15;96 Suppl 1:3-9. Med Klin (Munich). 2001. PMID: 11603113 German.
• Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?

  McNaughton H, Kayes N, McPherson K. McNaughton H, et al. N Z Med J. 2006 Apr 21;119(1232):U1939. N Z Med J. 2006. PMID: 16633398
• Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.

  Horowski R, Stürzebecher CS, Kapp JF. Horowski R, et al. Funct Neurol. 2001 Apr-Jun;16(2):117-28. Funct Neurol. 2001. PMID: 11495417 Review. No abstract available.
• The use of interferon beta at the time of initial diagnosis of multiple sclerosis.

  Pender MP. Pender MP. J Clin Neurosci. 2001 Jul;8(4):381-2. doi: 10.1054/jocn.2001.0913. J Clin Neurosci. 2001. PMID: 11437589 Review. No abstract available.